The Race to Stop Alzheimer’s: Can Early Intervention Change the Narrative?

A New Frontier in Alzheimer’s Research

For over a century, the medical community has struggled to treat Alzheimer’s disease, typically intervening only after patients exhibit clear signs of cognitive decline. However, a shift is underway as scientists investigate a provocative question: could Alzheimer’s be halted before the first symptoms ever appear? This approach focuses on clearing amyloid plaques—protein clusters believed to drive the disease—well before a patient forgets keys or struggles with daily tasks.

Maritza Ciliberto, a 57-year-old retired school principal, is among a small cohort of participants in the Dominantly Inherited Alzheimer Network (DIAN) trial at Washington University School of Medicine in St. Louis. Having lost her mother, grandmother, and several other relatives to a rare, inherited form of early-onset Alzheimer’s, Ciliberto has spent the last decade receiving intravenous anti-amyloid infusions every two weeks. Like other participants, she faces the reality of a lifelong treatment regimen that carries significant risks, including potential brain bleeding.

The Timing of Treatment

The efficacy of anti-amyloid drugs has been a subject of intense debate. While the FDA has approved newer therapies designed to flush out brain plaques, independent reviews, such as the Cochrane Review, have described their dementia-slowing effects as “trivial” while noting the risk of serious side effects. Dr. Randall Bateman, the neurologist leading the DIAN trial, suggests that previous failures may stem from timing. “When you look at them, the earlier the person was when they started that treatment trial, the better off they did,” Bateman noted. He believes that if current data holds through 2030, it could provide evidence that the onset of dementia can be delayed.

Hope vs. Uncertainty

For participants like Ciliberto and Jake Heinrichs, a 52-year-old theater electrician who also lost family members to the disease, the trial represents more than just medical data—it represents a future. Heinrichs, who previously feared passing the disease to his children, credits the trial with giving him the confidence to start a family. “In Jake and other people’s cases, they are discovering that Alzheimer’s is going to be a chronic condition—potentially—rather than a fatal condition,” said his wife, Rachel Chavkin.

However, experts remain cautious. Leading neurologist Richard Isaacson emphasizes that while these drugs might be a valuable tool for high-risk individuals, they are not a universal solution. He points out that some people with high levels of amyloid never develop dementia, while others may not respond to treatment despite doing everything correctly. “Once you’ve seen one person with Alzheimer’s, you’ve seen one person with Alzheimer’s,” Isaacson remarked, noting that he is not yet ready to recommend these drugs for prophylactic use in the general population.

Looking Toward the Future

The medical community is closely watching upcoming results from major pharmaceutical companies. Eli Lilly and Eisai are currently testing their anti-amyloid therapies in asymptomatic individuals who show high levels of amyloid in their brains, with initial results expected between 2027 and 2028. If successful, the research could transform Alzheimer’s from a “heartbreaking and inevitable march toward death” into a manageable, chronic condition similar to high blood pressure or diabetes.

For now, participants continue their routines, balancing the medical monitoring and potential side effects against the hope of a different outcome. For Ciliberto, the twice-monthly infusions have become a routine part of her life, one she approaches with optimism. “The science, now more than ever before, it’s projecting a very hopeful future,” she said.

Source: businessinsider.com